CardiAction

The CardiAction cardiovascular event risk indicator model has been validated to be predictive to ≈ 80% accuracy. CardiAction has found a way to eliminate the need for the blood test during initial screening. We have been developing the science, research and model since 2017. Commercial release commenced mid 2024. By minimising the data required, we can dramatically expand coverage by making the CardiAction event risk indicator available online directly to patients, anywhere, anytime. Reducing the pressure that Cardiovascular Disease (CVD) places on our populations, our health systems and healthcare budgets starts with identifying the unidentified at risk people and then providing them with effective interventions. The CardiAction screening model uses new and unique CVD biomarkers, estimated from simple and low-cost biometrics, compares these against central (heart) Blood Pressure (BP) data, and produces a more accurate indicator of the risk of an adverse CVD event. The CardiAction model predicts loss in arterial wall elasticity. The impact of smoking and diabetes is already implicated in these biometrics and therefore the resulting CardiAction Risk Indicator. Cardiovascular disease is a disease of the arterial walls caused by inflammation which stiffens them (smoking and diabetes are contributors to this inflammation.) Cholesterols need to be enabled by cellular inflammation to cause CVD. Identifying these changes means we can identify the risk of a cardiovascular event without directly measuring cholesterol via a blood test.

Website

https://www.cardiaction.com

External link for CardiAction

Industry

Hospitals and Health Care

Company size

2-10 employees

Headquarters

Melbourne, VIC

Type

Privately Held

Founded

2017

Specialties

Health Screening, Cardiovascular Disease, Digital Healthtech, and Mass Population Health Screening